We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Clinical Trial Shows Newly Approved Drug's Potential for Rare B-Cell Lymphoma

White and orange capsules spilling from a bottle on an orange surface.
Credit: Christina Victoria Craft/Unsplash

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Clinical Trial Shows Newly Approved Drug's Potential for Rare B-Cell Lymphoma "

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

In a multicenter phase 1 and 2 trial (BRUIN, NCT03740529), researchers from leading cancer centers across the globe, including the Medical College of Wisconsin (MCW) in Milwaukee, tested Bruton tyrosine kinase inhibitor (BTKi), pirtobrutinib, in patients with pre-treated mantle cell lymphoma (MCL). Results of the study, which assessed the efficacy of the drug in a cohort of 90 patients with poor survival prognosis, demonstrated the reversible BTKi drug to be both safe and effective in achieving inhibition of defective B-cells. The results were published by the Journal of Clinical Oncology on May 16.

MCL is an aggressive, rare subtype of B-cell non-Hodgkin lymphoma. Patients with relapsed/refractory MCL have historically had a median survival rate of less than 10 months. Resistance or intolerance to covalent BTKi drugs is common. Pirtobrutinib is the first BTKi of any kind to demonstrate durable efficacy in patients with relapsed/ refractory MCL previously treated with a covalent BTKi therapy.

In the study of patients between 46 and 87 years of age, with a median of 3 prior lines of therapy, more than half (57.8%) responded to the drug with a median duration of response of 21.6 months.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

“This trial builds on years of research to identify a safe and effective way to target b-cell signaling pathways and extend longevity for patients with MCL who have not responded to other forms of treatment,” said Nirav Shah, MD, associate professor of medicine at the Medical College of Wisconsin and the senior author on the study. “We now look forward to the results of future studies with pirtobrutinib, evaluating its role as a second line treatment option for patients with R/R MCL (NCT04662255, actively enrolling at the MCW Cancer Center).”

As the only academic medical center in southeast Wisconsin, and the largest cancer clinical trials program in the state, the MCW Cancer Center continues to offer a vast assortment of clinical trials and access to first-of-its-kind therapeutics for cancer patients in the region and beyond.

The study was sponsored by Loxo Oncology, Inc., a subsidiary of Eli Lilly and Company.

Reference: Wang ML, Jurczak W, Zinzani PL, et al. Pirtobrutinib in covalent BTK-inhibitor pre-treated mantle cell lymphoma. JCO. 2023:10.1200/JCO.23.00562. doi: 10.1200/JCO.23.00562

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.